Data-driven prioritization of high-risk individuals for weight loss interventions
Machine learning can identify people most likely to develop obesity-related health problems, helping doctors target weight-loss treatments more fairly across different populations.
Researchers developed OBSCORE, a machine-learning risk stratification framework trained in ~200,000 overweight/obese individuals, using 20 selected features from thousands tested to predict onset of 18 obesity-related complications including cardiovascular mortality over 10 years. The model was externally validated in multi-ancestry cohorts and in SURMOUNT-1 trial participants, showing robust discrimination and indicating that tirzepatide benefit extended across baseline risk strata — supporting population-level deployment for equitable treatment prioritization.
What the study was
- Study design
- Population-based ML model development and validation; secondary analysis of SURMOUNT-1 RCT participants
- Population
- Individuals with BMI >27 kg/m²; multi-ancestry validation cohorts; SURMOUNT-1 tirzepatide trial participants
- Sample size
- 200000
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Nature Medicine
Why it surfaced
Nature Medicine publication presenting a validated ML framework (OBSCORE) in ~200K individuals that predicts 18 obesity complications and stratifies who should receive GLP-1/tirzepatide therapy. Multi-ancestry validation and RCT integration (SURMOUNT-1) make this highly translatable. Directly relevant to GLP-1 deployment policy and precision obesity medicine.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.